Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19760508 | 0.91 | HPGD (0.51) | ALDH1A1HPGDADORA2BSMN1; SMN2ADORA2A | |
| SCHEMBL17859661 | 0.86 | KDM4E (0.49) | ALDH1A1HPGDMAPTTSHRHTT | |
| SCHEMBL17859685 | 0.86 | HPGD (0.55) | ALDH1A1HPGDADORA2BSMN1; SMN2ADORA2A | |
| SCHEMBL1945837 | 0.76 | HPGD (0.62) | ALDH1A1HPGDADORA2BSMN1; SMN2ADORA2A | |
| SCHEMBL31575420 | 0.74 | LMNA (0.60) | ALDH1A1HPGDSMN1; SMN2MAPTTSHR | |
| SCHEMBL17845828 | 0.72 | ALDH1A1 (0.73) | ALDH1A1HPGDSMN1; SMN2MAPTTSHR | |
| SCHEMBL31575417 | 0.72 | LMNA (0.60) | ALDH1A1HPGDSMN1; SMN2MAPTTSHR | |
| SCHEMBL17845823 | 0.72 | KDM4E (0.56) | ALDH1A1HPGDMAPTHTTMAPK1 | |
| SCHEMBL17626266 | 0.71 | ADORA2B (0.67) | ALDH1A1HPGDADORA2BSMN1; SMN2ADORA2A | |
| SCHEMBL31575400 | 0.70 | LMNA (0.86) | ALDH1A1SMN1; SMN2MAPTTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3904366-A1 | END CAPPED NUCLEIC ACID MOLECULES | Novartis AG (CH) | 2021-11-03 | — | — | EP | disclosed |
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2020-06-18 | — | — | US | disclosed |
| WO-2016098028-A1 | END CAPPED NUCLEIC ACID MOLECULES | NOVARTIS AG (CH) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190132-A1 | NOVEL 3' END CAPS, 5' END CAPS AND COMBINATIONS THEREOF FOR THERAPEUTIC RNA | RNGTT, NSUN2, NSUN3 | ALDH1A1 3871/4885HPGD 4849/4885ADORA2B 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.